RTTNews | Oct 6, 2021 08:56AM EDT

08:56 Wednesday, October 6, 2021 (RTTNews.com) - Acer Therapeutics Inc. (ACER) and its collaboration partner, RELIEF THERAPEUTICS Holding SA announced the FDA has accepted for filing the New Drug Application (NDA) for ACER-001 for the treatment of patients with Urea Cycle Disorders. The FDA has assigned a PDUFA target action date of June 5, 2022.

"In parallel with Acer's activities, we continue to execute on our global commercial strategy for ACER-001 which includes our intended submission of a Marketing Authorization Application for the treatment of patients with UCDs in Europe in Q2/Q3 2022," said Jack Weinstein, CFO of Relief.

Read the original article on RTTNews ( https://www.rttnews.com/3230867/acer-therapeutics-fda-to-review-nda-for-acer-001-quick-facts.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved